Dupilumab
| Evidence Level: L3 | Predicted Indications: 9 |
Table of Contents
Dupilumab: Bronchitis
One-Sentence Summary
Dupilumab is a monoclonal antibody originally used to treat atopic dermatitis (eczema). The TxGNN model predicts it may be effective for bronchitis, but the supporting evidence is indirect: 1 related Phase 2 trial (in chronic rhinosinusitis) and 11 publications, mostly on asthma and COPD.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in the local data |
| Predicted New Indication | Bronchitis |
| TxGNN Prediction Score | 0.9992 |
| Evidence Level | L3 |
| Australia Market Status | Listed on the PBS Schedule (1 of 1 items) – TGA (ARTG) registration status is not included in this data |
| Number of PBS Items | 1 (valid: 1) |
| Recommended Decision | Hold (research question) |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not available in the data compiled for this report. Based on the published literature, dupilumab is an antibody against the IL-4 receptor alpha subunit (IL-4Rα). It blocks both IL-4 and IL-13 signalling, which drive type 2 inflammation.
Atopic dermatitis is a type 2 inflammatory disease. Type 2 inflammation also underlies eosinophilic airway disease such as asthma and a subset of COPD, so a link to airway conditions is biologically plausible.
“Bronchitis” is a broad, heterogeneous label. Benefit is plausible mainly in type 2 or eosinophilic phenotypes, such as COPD with a chronic bronchitis pattern or eosinophilic plastic bronchitis. The strongest adjacent signal is in type 2 COPD, where real-world cohorts and trial-derived comparisons have been reported. This is indirect evidence and does not establish efficacy in bronchitis generally.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrolment | Key Findings |
|---|---|---|---|---|
| NCT04362501 | Phase 2 | Completed | 33 | Randomised, double-blind, placebo-controlled study of dupilumab in chronic rhinosinusitis without nasal polyps. This is an upper-airway condition linked by shared type 2 biology; it does not test bronchitis directly |
No registered trial directly tests dupilumab in bronchitis. No ANZCTR identifiers were available in the data compiled for this report.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 34597534 | 2022 | RCT (open-label extension) | Lancet Respir Med | TRAVERSE: long-term safety and efficacy of dupilumab in moderate-to-severe asthma |
| 30273510 | 2019 | Meta-analysis | J Asthma | Safety and efficacy of dupilumab in uncontrolled asthma across randomised trials |
| 42617837 | 2026 | Cohort (indirect comparison) | Chest | Mepolizumab and dupilumab showed no significant difference in reducing exacerbations in eosinophilic COPD |
| 42839285 | 2026 | Cohort | Respir Res | German multicentre real-world effectiveness of dupilumab in COPD |
| 42511891 | 2026 | Case series | Biomedicines | 12 patients with type 2 COPD, mainly chronic bronchitis phenotype, treated with dupilumab on compassionate use |
| 38488768 | 2024 | Review | Pediatr Pulmonol | Novel therapies for eosinophilic paediatric plastic bronchitis |
| 42773542 | 2026 | Review | Eur J Clin Invest | Updates in COPD management, including targeted therapies |
| 39904363 | 2025 | Review | Tuberc Respir Dis | Pharmacologic therapies for preventing COPD exacerbations |
| 30196731 | 2018 | Review | Expert Opin Pharmacother | Managing asthma with smoking-induced airway disease, including chronic bronchitis |
| 41672525 | 2026 | Case report | Intern Med (Tokyo) | Two cases of eosinophilic bronchiolitis treated with biologics, including dupilumab |
Australia Market Information
| ARTG Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| ARTG 12291X | Dupixent | Injection 200 mg in 1.14 mL single dose pre-filled syringe | Not available in the data compiled for this report |
Safety Considerations
Key warnings and contraindications were not available in the data compiled for this report. Please refer to the TGA-approved Product Information (PI) for these details.
Drug interactions: 53 interactions were identified; the main ones are listed below.
- Major: adalimumab, baricitinib, certolizumab pegol, cladribine. These are mostly combinations with other immunosuppressive agents.
- Moderate: warfarin, roflumilast, azathioprine, cyclosporine, anakinra, alemtuzumab, denosumab, dimethyl fumarate, and a live cholera vaccine.
- Minor: zinc salts (acetate, gluconate, sulfate, chloride).
Conclusion and Next Steps
Decision: Hold
Rationale: The TxGNN score is high, but no trial tests dupilumab in bronchitis. The evidence is adjacent (asthma, type 2 COPD, and a chronic rhinosinusitis trial) and “bronchitis” is too heterogeneous a label. This is a research question, not a candidate for clinical repurposing.
To proceed, the following is needed:
- Define a specific type 2 or eosinophilic bronchitis or COPD phenotype to target
- Review the Australian TGA PI and the approved indication text to confirm current labelled uses and safety information (the PI data were missing)
- Mechanism of action data to complete the mechanistic analysis
- Controlled trial evidence in the chosen phenotype, including a check of the COPD pivotal trial data and the Australian regulatory status for that use
- A safety monitoring plan covering immunosuppressant co-medications and known dupilumab adverse effects such as conjunctivitis
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.